Mr. Sina Habibi reports

COGNICA SHOWN TO SAVE TENS OF MILLIONS OF DOLLARS IN HEALTHCARE COSTS ANNUALLY AND IMPROVE PATIENT OUTCOMES IN THE UK NATIONAL HEALTH SERVICE

Cognetivity Neurosciences Ltd. has provided an update on the peer-reviewed publication of the health economic impact of its Cognica technology in the journal Frontiers in Public Health. This research evaluated the economic impact and clinical benefits of Cognica compared with standard cognitive tests for dementia screening in primary care and initial patient triage in memory clinics in the United Kingdom National Health Service (NHS), showing an initial saving of over 40 million British pounds per year if deployed in both primary and secondary care.

In a landscape where health care budgets are continually under scrutiny, Cognica's ability to reduce costs has shown to have the potential for substantial positive impact in large health care systems. The tool's cost-effectiveness is demonstrable in both primary care and specialized memory clinic settings, outperforming traditional cognitive assessments, which require substantial clinician time to administer. Over and above these cost savings, the use of Cognica translates into quality-of-life improvements, as evidenced by the quality-adjusted life years (QALYs) gains that show the benefits to patients through the use of the technology.

The article underscores the potential for Cognica to yield significant cost savings for health care systems like the NHS. These estimates focus solely on immediate savings and do not account for downstream benefits such as reduced caregiver burden, lower lifetime care costs, and other indirect advantages stemming from earlier and more accurate diagnoses of diseases like Alzheimer's disease. When these broader impacts are considered, the overall financial benefit of incorporating Cognica into clinical practice could increase even more substantially. Currently, the annual cost of caring for individuals with dementia in the United Kingdom ranges from 100,000 British pounds to as much as 500,000 British pounds.

Cognetivity's co-founder and chief information officer, Dr. Seyed Khaligh-Razavi, commented: "It is always good to build on the high quality of our science and research with further peer-reviewed articles in high-impact journals. These results clearly show the massive potential for cost savings for health care payers and providers such as the U.K.'s NHS through the use of Cognica. At such a critical juncture for health care systems globally, faced with the dual challenges of an aging population and a surge in dementia cases, it is vital that doctors have the right tools that enable them to help their patients wherever they are and to make health care systems more efficient."

He added, "This is particularly timely given the recent approvals of new treatments for Alzheimer's disease, such as Eisai's Leqembi, along with other upcoming disease-modifying therapies for which it is essential to identify disease at an early stage at scale, something that Cognica can provide."

Currently deployed in clinical practice in multiple countries and diverse settings, Cognica continues to amass compelling evidence supporting its unique capacity for reliable and cost-effective early detection and monitoring at scale, solidifying its role in the continuing global fight against Alzheimer's disease.

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company that has developed a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity's Cognica uses artificial intelligence and machine learning technology to test the performance of large areas of the brain to help detect early signs of cognitive dysfunction. Cognica is currently available for clinical use in the United States, United Kingdom, Europe, Canada and the Middle East, with regulatory approval in other regions expected later in 2023.

We seek Safe Harbor.